Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maralixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maralixibat SCHEMBL6336186 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564749 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564753 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL10013954 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL18176641 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL27193090 | 0.97 | SLC10A2 (0.96) | SLC10A2 | |
| SCHEMBL27193088 | 0.92 | SLC10A2 (0.87) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL6336188 | 0.92 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL27206765 | 0.91 | SLC10A2 (0.85) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL27206760 | 0.91 | SLC10A2 (0.84) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116891-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| WO-2024059163-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024121434-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024091445-A1 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240116891-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024059163-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023203248-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | WO | disclosed |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | US | disclosed |
| US-20210322360-A1 | SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES | MICELLE BIOPHARMA, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210322359-A1 | SICKLE CELL DISEASE TREATMENT UTILIZING OMEGA-3 FATTY ACIDS | MICELLE BIOPHARMA, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-1091953-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE & CO (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1331225-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | G.D. SEARLE & CO. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1042314-B1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | SEARLE & CO (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6387924-B2 | ATHEROSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTILIPIDEMIC AGENTS | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| US-6369220-B1 | OXIDIZING AN ARYL-3-HYDROXYPROPYLSULFIDE; OXIDIZING 3-HYDROXY GROUP INTO ARYL-3-PROPANALSULFOXIDE; CYCLIZATION | G.D. SEARLE, LLC | 2002-04-09 | — | — | US | disclosed |
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. | 2002-01-31 | — | — | US | disclosed |
| US-6262277-B1 | IN MEDICINE FOR PROPHYLAXIS AND THERAPY OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| US-6107494-A | FOR TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | SLC10A1, SLC10A2, SLC10A6 | SLC10A2 2/4885 |
| US-20240116891-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MPST, SULT2A1, CYP2B6 | SLC10A2 316/4885 |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.